Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:CADL NASDAQ:HROW NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.11+1.8%$3.32$1.89▼$5.82$1.50B0.626.89 million shs5.17 million shsCADLCandel Therapeutics$7.02+0.3%$5.64$3.79▼$14.60$351.72M-0.911.10 million shs597,820 shsHROWHarrow$36.19-2.8%$31.16$20.85▼$59.23$1.37B0.41432,278 shs325,350 shsWVEWAVE Life Sciences$8.40+0.1%$7.01$5.04▼$16.74$1.31B-1.011.60 million shs1.40 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+1.79%+14.06%+34.47%+98.83%+69.77%CADLCandel Therapeutics+0.29%+4.15%+44.74%+40.96%+10.38%HROWHarrow-2.82%+0.84%+14.71%+41.64%+51.61%WVEWAVE Life Sciences+0.12%+0.72%+22.63%+24.81%+36.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.235 of 5 stars3.51.00.00.02.63.30.0CADLCandel Therapeutics2.0909 of 5 stars3.61.00.00.02.21.70.6HROWHarrow2.6039 of 5 stars3.51.00.00.03.32.50.6WVEWAVE Life Sciences4.4882 of 5 stars3.52.00.04.82.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 3.00Buy$8.7571.23% UpsideCADLCandel Therapeutics 3.20Buy$22.00213.39% UpsideHROWHarrow 3.00Buy$63.8376.38% UpsideWVEWAVE Life Sciences 2.92Moderate Buy$20.15139.93% UpsideCurrent Analyst Ratings BreakdownLatest CADL, ABCL, HROW, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/14/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.007/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$76.007/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025ABCLAbCellera BiologicsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025ABCLAbCellera BiologicsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.006/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.006/23/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.006/12/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.006/11/2025WVEWAVE Life SciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.006/10/2025HROWHarrowWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$23.11M65.98N/AN/A$3.58 per share1.43CADLCandel TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AHROWHarrow$212.86M6.24$0.13 per share272.30$1.95 per share18.56WVEWAVE Life Sciences$108.30M12.07N/AN/A$1.37 per share6.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/7/2025 (Estimated)CADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)HROWHarrow-$17.48M-$0.56N/A90.48N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%7/30/2025 (Estimated)Latest CADL, ABCL, HROW, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CADLCandel Therapeutics-$0.17N/AN/AN/AN/AN/A8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17N/AN/AN/A$7.55 millionN/A8/6/2025Q2 2025HROWHarrow$0.01N/AN/AN/A$64.23 millionN/A7/30/2025Q2 2025WVEWAVE Life Sciences-$0.28N/AN/AN/A$11.52 millionN/A5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/8/2025Q1 2025WVEWAVE Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15CADLCandel Therapeutics0.014.644.64HROWHarrow2.010.910.85WVEWAVE Life SciencesN/A2.952.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%CADLCandel Therapeutics13.93%HROWHarrow72.76%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%CADLCandel Therapeutics16.60%HROWHarrow15.16%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableHROWHarrow18036.69 million31.12 millionOptionableWVEWAVE Life Sciences240155.56 million118.26 millionOptionableCADL, ABCL, HROW, and WVE HeadlinesRecent News About These CompaniesWAVE Life Sciences (WVE) to Release Quarterly Earnings on WednesdayJuly 25 at 4:42 PM | marketbeat.comNew York State Common Retirement Fund Acquires 41,429 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)July 25 at 3:52 AM | marketbeat.comWave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025July 23 at 8:30 AM | globenewswire.comHussman Strategic Advisors Inc. Has $848,000 Stake in WAVE Life Sciences Ltd. (NASDAQ:WVE)July 19, 2025 | marketbeat.comPrincipal Financial Group Inc. Acquires 59,399 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)July 19, 2025 | marketbeat.comBreaking Down WAVE Life Sciences: 4 Analysts Share Their ViewsJuly 16, 2025 | benzinga.comCitigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationJuly 16, 2025 | msn.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Should You Buy?July 16, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Coverage Initiated at CitigroupJuly 16, 2025 | marketbeat.comWave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific SessionsJuly 15, 2025 | msn.comWAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?July 15, 2025 | marketbeat.comLeerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24July 11, 2025 | msn.comNASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.comJuly 11, 2025 | investing.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?July 9, 2025 | marketbeat.comWAVE Life Sciences Ltd. Company & People | WVE | Barron'sJuly 7, 2025 | barrons.comWave Life Sciences: Upgrading Rating To Buy After Turbulent 10 MonthsJuly 7, 2025 | seekingalpha.comWave Life Sciences: Speculative, But PromisingJuly 7, 2025 | seekingalpha.comWave Life Sciences Ltd. (WVE) - Yahoo FinanceJuly 6, 2025 | finance.yahoo.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 6, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 6, 2025 | marketbeat.comMoody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)July 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCADL, ABCL, HROW, and WVE Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.11 +0.09 (+1.79%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$5.13 +0.02 (+0.39%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Candel Therapeutics NASDAQ:CADL$7.02 +0.02 (+0.29%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.98 -0.04 (-0.51%) As of 07/25/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Harrow NASDAQ:HROW$36.19 -1.05 (-2.82%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$36.76 +0.57 (+1.56%) As of 07/25/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.WAVE Life Sciences NASDAQ:WVE$8.40 +0.01 (+0.12%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$8.40 0.00 (-0.01%) As of 07/25/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
